About Careers Internship MedBlog Contact us

Drug Marketing Techniques Appear To Flout Patients' Safety Norms

by Savitha C Muppala on December 4, 2008 at 1:21 PM
 Drug Marketing Techniques Appear To Flout Patients' Safety Norms

A report has cast doubts on the manner in which drugs are released into the market, faster than ever before, raising concerns about patients' safety.

Author David Kao, from the University of Colorado Health Sciences Center, says that the pressure on drug regulatory bodies to make new medicines available more quickly has raised fresh concerns about patients' safety.


He reviewed trends in drug approval times in the U.S., and came up with suggestions as to how marketing techniques could be used to improve the way new medicines were monitored.

Publishing his report in the online edition of the British Medical Journal (BMJ), he has highlighted the fact that marketing techniques these days are so sophisticated that once a drug has been approved, the products can be released on websites within 90 minutes.

He even points out how 188 million patients had been targeted by the marketing campaign within 14 days after Merck's new treatment for high blood sugar levels, sitagliptin, was approved.

Kao thinks that a large number of patients may be exposed to unknown risks if people try any new medicine so quickly.

The reviewer also says that regulatory agencies often depend on drug companies for funding, and collect fees so as to hire staff to review new medicines more quickly.

He recommends improvement in the systems for reporting adverse drug reactions, and the use of the very same effective drug marketing techniques to do so.

Kao says that U.S. laws already compel TV adverts to instruct patients experiencing negative side effects to report their symptoms to the FDA, and this could be expanded to include campaigns dedicated to drug safety monitoring.

According to him, the only drug monitoring system that will minimise unknown risks must involve all the key players in healthcare, including doctors, regulatory bodies, drug companies and patients.

Source: ANI
Font : A-A+



Recommended Readings

Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Drug Marketing Techniques Appear To Flout Patients' Safety Norms Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests